3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Withdrawn
1
Recruiting
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
53
Lymphoma, Mantle-Cell
34
Lymphoma, Large B-Cell, Diffuse
18
Lymphoma, Follicular
18
Lymphoma
15
Lymphoma, Non-Hodgkin
13
Waldenstrom Macroglobulinemia
12
Lymphoma, B-Cell
12
Recurrence
9
Lymphoma, B-Cell, Marginal Zone
9
Leukemia
6
Bronchiolitis Obliterans Syndrome
6
Multiple Myeloma
5
Leukemia, Lymphoid
5
Leukemia, B-Cell
5
Hodgkin Disease
5
Hematologic Neoplasms
4
Burkitt Lymphoma
4
Neoplasms
3
Graft vs Host Disease
3
Lung Neoplasms
2
Leukemia, Myeloid, Acute
2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Chromosome 17 deletion
2
Carcinoma, Renal Cell
2
Carcinoma, Non-Small-Cell Lung
2
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Neuroendocrine Tumors
1
Interventions
dacetuzumab
6
blinatumomab
6
Rituximab
4
Epoetin Alfa
4
Lenalidomide
3
Dexamethasone
3
Darbepoetin alfa
3
Cyclophosphamide
3
Bortezomib
3
Therapeutics
2
Everolimus
2
Early Intervention, Educational
2
Alemtuzumab
2
venetoclax
1
vandetanib
1
tirbanibulin
1
tetulomab tetraxetan lu-177
1
ponatinib
1
plerixafor
1
pembrolizumab
1
pegaspargase
1
isatuximab
1
imetelstat
1
ibrutinib
1
fludarabine
1
ficlatuzumab
1
ferrous sulfate
1
ferric gluconate
1
ferric carboxymaltose
1
durvalumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Lymphoproliferative Disorders
×
ibrutinib
×
Clear all
NCT02733042
2023-11-18
FUSION NHL 001
Celgene
Phase 1/2
Completed
106 enrolled
48 charts